Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accumulated Expenses (2016 - 2025)

Wave Life Sciences' Accumulated Expenses history spans 11 years, with the latest figure at $26.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 72.97% year-over-year to $26.6 million; the TTM value through Dec 2025 reached $26.6 million, up 72.97%, while the annual FY2025 figure was $26.6 million, 72.97% up from the prior year.
  • Accumulated Expenses reached $26.6 million in Q4 2025 per WVE's latest filing, up from $4.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $26.6 million in Q4 2025 to a low of $476000.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $6.9 million, with a median of $5.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: plummeted 92.85% in 2022, then skyrocketed 1128.65% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $10.2 million in 2021, then rose by 20.69% to $12.3 million in 2022, then grew by 14.47% to $14.1 million in 2023, then rose by 9.19% to $15.4 million in 2024, then skyrocketed by 72.97% to $26.6 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Accumulated Expenses are $26.6 million (Q4 2025), $4.6 million (Q3 2025), and $1.0 million (Q2 2025).